Pharmacovigilance Risk Assessment Ctte. Oct 22 EMA recommends measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders EMA safety committee (PRAC) recommended measures to minimise risks of serious side effects associated with Janus kinase (JAK) inhibitors used to treat various chronic inflammatory disorders. Side effects include cardiovascular conditions,…
